hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine
暂无分享,去创建一个
Jules C. Hancox | Christopher E. Dempsey | John S. Mitcheson | J. Hancox | C. Dempsey | A. El Harchi | J. Mitcheson | Dario Melgari | Yihong Zhang | G. Ng | Aziza El Harchi | Dario Melgari | Kieran E. Brack | Chuan Zhang | Yihong Zhang | G. André Ng | K. Brack | Chuan Zhang
[1] David K. Jones,et al. hERG 1b is critical for human cardiac repolarization , 2014, Proceedings of the National Academy of Sciences.
[2] J. Tardif,et al. Ivabradine in stable coronary artery disease without clinical heart failure. , 2014, The New England journal of medicine.
[3] C. Du,et al. Ranolazine inhibition of hERG potassium channels: Drug–pore interactions and reduced potency against inactivation mutants , 2014, Journal of molecular and cellular cardiology.
[4] J. Bourke,et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials , 2014, Heart.
[5] R. Lagioia,et al. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control , 2014, Drug design, development and therapy.
[6] S. Mittal. Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. , 2014, The Journal of the Association of Physicians of India.
[7] Jules C. Hancox,et al. Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block , 2014, J. Chem. Inf. Model..
[8] G. Cocco,et al. Torsades de Pointes Induced by the Concomitant Use of Ivabradine and Azithromycin: An Unexpected Dangerous Interaction , 2014, Cardiovascular Toxicology.
[9] Lei Tian,et al. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. , 2013, Clinical therapeutics.
[10] M. Nardini,et al. Identification of the Molecular Site of Ivabradine Binding to HCN4 Channels , 2013, PloS one.
[11] Yi H. Zhang,et al. Molecular determinants of hERG potassium channel inhibition by disopyramide. , 2012, Journal of molecular and cellular cardiology.
[12] J. Papp,et al. Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions. , 2011, European journal of pharmacology.
[13] Charlotte K. Colenso,et al. The hERG K+ channel S4 domain L532P mutation: Characterization at 37 °C , 2011, Biochimica et biophysica acta.
[14] J. Coote,et al. Vagus nerve stimulation protects against ventricular fibrillation independent of muscarinic receptor activation. , 2011, Cardiovascular research.
[15] J. Tardif,et al. Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts. , 2011, American journal of physiology. Heart and circulatory physiology.
[16] C. Du,et al. Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform. , 2011, Biochemical and biophysical research communications.
[17] S. Leslie,et al. Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure , 2011, Therapeutic advances in drug safety.
[18] Yi H. Zhang,et al. Acidosis Impairs the Protective Role of hERG K+ Channels Against Premature Stimulation , 2010, Journal of cardiovascular electrophysiology.
[19] J. Coote,et al. Vagus nerve stimulation inhibits the increase in Ca2+ transient and left ventricular force caused by sympathetic nerve stimulation but has no direct effects alone – epicardial Ca2+ fluorescence studies using fura‐2 AM in the isolated innervated beating rabbit heart , 2010, Experimental physiology.
[20] R. Ferrari,et al. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. , 2009, Cardiovascular research.
[21] Liang Guo,et al. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. , 2009, Journal of pharmacological and toxicological methods.
[22] J. Hancox,et al. hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome , 2009, Biochemical and biophysical research communications.
[23] Yumi N Imai,et al. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. , 2009, Journal of medicinal chemistry.
[24] J. Hancox,et al. A method for making rapid changes of superfusate whilst maintaining temperature at 37°C , 1996, Pflügers Archiv.
[25] J. Hancox,et al. Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs , 2008, British journal of pharmacology.
[26] Jamie I Vandenberg,et al. Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.
[27] Michael J. Ackerman,et al. Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome , 2008, Circulation research.
[28] Jules C Hancox,et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.
[29] P. Bois,et al. Molecular regulation and pharmacology of pacemaker channels. , 2007, Current pharmaceutical design.
[30] J. Coote,et al. Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart. , 2007, Cardiovascular research.
[31] D. DiFrancesco,et al. Properties of ivabradine‐induced block of HCN1 and HCN4 pacemaker channels , 2006, The Journal of physiology.
[32] J. Ménard,et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. , 2006, British journal of clinical pharmacology.
[33] A. Camm,et al. Novel If current inhibitor ivabradine: safety considerations. , 2006, Advances in cardiology.
[34] J. Hancox,et al. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. , 2006, Journal of molecular and cellular cardiology.
[35] Jules C. Hancox,et al. The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: Mechanism of gain-in-function determined at 37 °C , 2005 .
[36] R. Brugada,et al. Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG , 2005, Journal of cardiovascular electrophysiology.
[37] E. Jones,et al. Cardiac IKr Channels Minimally Comprise hERG 1a and 1b Subunits* , 2004, Journal of Biological Chemistry.
[38] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[39] S. Viskin,et al. Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors , 2003, Medicine.
[40] J. Hancox,et al. Inhibition of HERG K+ Current and Prolongation of the Guinea‐Pig Ventricular Action Potential by 4‐Aminopyridine , 2003, The Journal of physiology.
[41] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[42] C. Lau,et al. Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology , 2003, Drugs in R&D.
[43] D. DiFrancesco,et al. Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine , 2002, The Journal of general physiology.
[44] Youxing Jiang,et al. Crystal structure and mechanism of a calcium-gated potassium channel , 2002, Nature.
[45] Alan Garfinkel,et al. Electrical Restitution and Cardiac Fibrillation , 2002, Journal of cardiovascular electrophysiology.
[46] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[47] H. Duff,et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.
[48] A. Brown,et al. Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.
[49] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[50] J. Péglion,et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. , 1997, European journal of pharmacology.
[51] N. Copeland,et al. Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. , 1997, Circulation research.
[52] J. Lenfant,et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells , 1996, British journal of pharmacology.
[53] J. Tamargo,et al. Effects of the two enantiomers, S‐16257‐2 and S‐16260‐2, of a new bradycardic agent on guinea‐pig isolated cardiac preparations , 1995, British journal of pharmacology.
[54] J. Prost,et al. Electrophysiological effects of S 16257, a novel sino‐atrial node modulator, on rabbit and guinea‐pig cardiac preparations: comparison with UL‐FS 49 , 1994, British journal of pharmacology.